Imexpharm Corporation (HOSE:IMP)

Imexpharm Income Statement

Financials in millions VND. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Jan 1, 2024	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	2,452,365	2,205,120	1,994,037	1,643,707	1,266,597	1,369,422
Revenue Growth (YoY)	13.47%	10.59%	21.31%	29.77%	-7.51%	-2.35%
Cost of Revenue	1,366,285	1,181,634	1,010,064	824,152	669,657	750,104
Gross Profit	1,086,079	1,023,486	983,973	819,555	596,940	619,318
Selling, General & Admin	608,581	608,328	602,926	523,055	362,868	356,763
Operating Expenses	608,581	608,328	602,926	523,055	362,868	356,763
Operating Income	477,499	415,158	381,047	296,500	234,072	262,555
Interest Expense	-14,546	-3,489	-6,036	-3,795	-5,496	-5,408
Interest & Investment Income	1,057	7,929	19,877	19,853	12,364	7,015
Currency Exchange Gain (Loss)	1,589	2,410	2,613	-2,053	3,436	1,882
Other Non Operating Income (Expenses)	-5,011	-19,555	-20,221	-19,448	-9,413	-10,173
EBT Excluding Unusual Items	460,588	402,453	377,279	291,059	234,963	255,870
Gain (Loss) on Sale of Investments	1,741	1,740	-6.02	345.28	3,896	-429.04
Gain (Loss) on Sale of Assets	1,020	-	-	-	-	-
Pretax Income	463,349	404,193	377,273	291,404	238,859	255,441
Income Tax Expense	101,091	83,331	77,717	67,864	49,764	45,744
Net Income	362,258	320,862	299,556	223,540	189,095	209,697
Preferred Dividends & Other Adjustments	5,429	23,327	21,778	39,697	15,582	30,039
Net Income to Common	356,830	297,536	277,778	183,844	173,513	179,658
Net Income Growth	32.89%	7.11%	34.01%	18.22%	-9.83%	29.13%
Shares Outstanding (Basic)	170	154	154	154	154	150
Shares Outstanding (Diluted)	170	154	154	154	154	150
Shares Change (YoY)	8.16%	-	-0.00%	-0.00%	2.92%	0.86%
EPS (Basic)	2101.05	1931.94	1803.65	1193.71	1126.63	1200.54
EPS (Diluted)	2101.05	1931.94	1803.65	1193.64	1126.63	1200.43
EPS Growth	32.26%	7.11%	51.11%	5.95%	-6.15%	24.64%
Free Cash Flow	-87,959	119,497	-103,064	279,250	182,024	-16,531
Free Cash Flow Per Share	-517.91	775.91	-669.21	1813.19	1181.89	-110.47
Dividend Per Share	500.000	500.000	454.546	432.901	649.351	649.351
Dividend Growth	10.00%	10.00%	5.00%	-33.33%	-	95.00%
Gross Margin	44.29%	46.41%	49.35%	49.86%	47.13%	45.23%
Operating Margin	19.47%	18.83%	19.11%	18.04%	18.48%	19.17%
Profit Margin	14.55%	13.49%	13.93%	11.19%	13.70%	13.12%
Free Cash Flow Margin	-3.59%	5.42%	-5.17%	16.99%	14.37%	-1.21%
EBITDA	581,484	519,393	463,689	356,886	294,484	315,916
EBITDA Margin	23.71%	23.55%	23.25%	21.71%	23.25%	23.07%
D&A For EBITDA	103,986	104,235	82,642	60,386	60,412	53,361
EBIT	477,499	415,158	381,047	296,500	234,072	262,555
EBIT Margin	19.47%	18.83%	19.11%	18.04%	18.48%	19.17%
Effective Tax Rate	21.82%	20.62%	20.60%	23.29%	20.83%	17.91%
Revenue as Reported	2,452,365	2,205,120	1,994,037	1,643,707	1,266,597	1,369,422
Advertising Expenses	-	170,332	175,099	123,665	110,468	74,360

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.